Gerace v. Biotheranostics, Inc.

2022 Ohio 302, 184 N.E.3d 915
CourtOhio Court of Appeals
DecidedFebruary 3, 2022
Docket110440
StatusPublished
Cited by1 cases

This text of 2022 Ohio 302 (Gerace v. Biotheranostics, Inc.) is published on Counsel Stack Legal Research, covering Ohio Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gerace v. Biotheranostics, Inc., 2022 Ohio 302, 184 N.E.3d 915 (Ohio Ct. App. 2022).

Opinion

[Cite as Gerace v. Biotheranostics, Inc., 2022-Ohio-302.]

COURT OF APPEALS OF OHIO

EIGHTH APPELLATE DISTRICT COUNTY OF CUYAHOGA

JAMES GERACE, :

Plaintiff-Appellant, : No. 110440 v. :

BIOTHERANOSTICS, INC., ET AL., :

Defendants-Appellees. :

JOURNAL ENTRY AND OPINION

JUDGMENT: AFFIRMED RELEASED AND JOURNALIZED: February 3, 2022

Civil Appeal from the Cuyahoga County Court of Common Pleas Case No. CV-20-939288

Appearances:

Polk Kabat, LLP, Shannon J. Polk, Mark F. Humenik, and Daniel M. Connell, for appellant.

Jackson Lewis P.C., Vincent J. Tersigni, and Donald G. Slezak, for appellees.

LISA B. FORBES, J.:

Plaintiff James Gerace (“Gerace”) appeals from the trial court’s

judgment dismissing his complaint against his former employer Biotheranostics,

Inc., and three of the company’s executives: Lisa Whitmyer, Vice President of Marketing; Don Hardison, Chief Executive Officer; and Matt Sargent, Chief

Commercial Officer (collectively “Defendants”). After reviewing the facts of the case

and pertinent law, we affirm the lower court’s judgment.

I. Facts and Procedural History

This case concerns, in part, whether California law can properly

govern Gerace’s claims in an Ohio state court. Gerace filed his complaint against the

Defendants in the Cuyahoga County Common Pleas Court setting forth three claims:

California unfair business/trade practices; wrongful discharge in violation of public

policy under California law; and wrongful discharge in violation of Ohio public

policy.1 The gist of all three claims is that Defendants improperly terminated

Gerace’s employment.

A brief summary of the parties and places is a logical place to start.

Viewing the allegations in a light most favorable to the plaintiff, as we must when

reviewing a lower court’s ruling on a motion to dismiss, the following information is

taken from Gerace’s complaint. Gerace is a resident of Ohio, who lived and worked

in Ohio at all times pertinent to this case. Biotheranostics is a Delaware corporation

with a principal place of business in California and regularly conducts business in

Ohio. Whitmyer is a resident of Ohio, Hardison is a resident of California, and

Sargent is a resident of Arizona.

1Claims one and two are against Biotheranostics and Doe/XYZ Corporation Defendants. Claim three is against all Defendants. In January 2016, Biotheranostics hired Gerace to market its “most

significant product, Breast Cancer Index [“BCI”], to hospitals and oncologists

specializing in the treatment of breast cancer.” The National Comprehensive Cancer

Network (“NCCN”) is a nonprofit organization “of 28 leading cancer centers devoted

to patient care, research, and education.” During the 5th Annual Cleveland Breast

Cancer Summit, which was held in late August 2019, Dr. Jame Abraham (“Dr.

Abraham”), who was the director of the Breast Cancer Oncology Program at the

Cleveland Clinic, as well as an NCCN panelist, “spoke favorably about

Biotheranostics’s [BCI], giving the impression that the NCCN had approved, or

would likely approve [BCI] for inclusion in its guidelines.”

During a break at the summit, Gerace thanked Dr. Abraham “for his

positive comments about” BCI, and Dr. Abraham “became extremely upset, most

likely as a result of a concern that he had violated NCCN’s” policies by appearing to

unofficially endorse BCI. Dr. Abraham communicated to the Defendants his

disapproval of Gerace, ultimately stating that he was “done with Biotheranostics.”

On August 27, 2019, Biotheranostics terminated Gerace’s employment. The next

day, Dr. Abraham communicated to Defendants that he “could work with

Biotheranostics after all.”

On March 22, 2021, the court granted Defendants’ motion to dismiss,

stating in part as follows:

Count one of plaintiff’s complaint, California unfair business/trade practices, pursuant to Cal. Bus. & Prof. Code § 17000 et seq. and count [two] wrongful discharge in violation of public policy under Cal. Penal Code § 641.3 and Cal. Bus. & Prof. Code §17200 against Defendants * * * are dismissed as the operative facts alleged in the complaint occurred in Ohio, and therefore, Ohio law governs, and California’s presumption against the extraterritorial application of state law preclude the claims.

Count three of plaintiff’s complaint, wrongful discharge in violation of Ohio public policy * * * is dismissed as plaintiff failed to establish the clarity and jeopardy elements required to succeed on a wrongful discharge in violation of public policy claim.

It is from this order that Gerace appeals.

II. Law and Analysis

A. Civ.R. 12(B)(6) Motion to Dismiss

We review rulings on Civ.R. 12(B)(6) motions to dismiss under a de

novo standard. “A motion to dismiss for failure to state a claim upon which relief

can be granted is procedural and tests the sufficiency of the complaint. * * * Under

a de novo analysis, we must accept all factual allegations of the complaint as true

and all reasonable inferences must be drawn in favor of the nonmoving party.”

NorthPoint Props. v. Petticord, 179 Ohio App.3d 342, 2008-Ohio-5996, 901 N.E.2d

869, ¶ 11 (8th Dist.). “For a trial court to grant a motion to dismiss for failure to state

a claim upon which relief can be granted, it must appear ‘beyond doubt from the

complaint that the plaintiff can prove no set of facts entitling her to relief.’” Graham

v. Lakewood, 2018-Ohio-1850, 113 N.E.3d 44, ¶ 47 (8th Dist.), quoting Grey v.

Walgreen Co., 197 Ohio App.3d 418, 2011-Ohio-6167, 967 N.E.2d 1249, ¶ 3 (8th

Dist.).

For ease of discussion, we address Gerace’s assignments of error out

of order. B. California’s Presumption Against the Extraterritorial Application of California Law Does Not Apply

In Gerace’s second assignment of error, he argues that the “trial court

erred * * * by determining * * * that California’s presumption against the

extraterritorial application of state law preclude[s] the claims.” Upon review, we

conclude that we need not look to California law because Ohio law governs the

claims in the instant case.

First, we note that appellate courts review a trial court’s choice-of-law

determination under a de novo standard. Holliday v. Ford Motor Co., 8th Dist.

Cuyahoga No. 86069, 2006-Ohio-284, ¶ 14. The Ohio Supreme Court has held that

“[w]hen confronted with a choice-of-law issue in a tort action * * * a presumption is

created that the law of the place of the injury controls unless another jurisdiction

has a more significant relationship to the lawsuit.” Morgan v. Biro Mfg. Co., 15 Ohio

St.3d 339, 342, 474 N.E.2d 286 (1984).

More specifically, Ohio courts have held that in a wrongful

termination case, the place where the plaintiff lost his or her employment is the place

of the injury. See Hoyt v. Nationwide Mut. Ins. Co., 10th Dist. Franklin No. 04AP-

941, 2005-Ohio-6367, ¶ 27 (applying Morgan to a wrongful termination case and

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wos v. Cleveland
2025 Ohio 1456 (Ohio Court of Appeals, 2025)

Cite This Page — Counsel Stack

Bluebook (online)
2022 Ohio 302, 184 N.E.3d 915, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gerace-v-biotheranostics-inc-ohioctapp-2022.